# Psychedelic retreats and ibogaine: what the evidence can tell us

If poisoning is suspected, contact a local emergency medical service immediately, even before symptoms appear. New sudden confusion on its own, or dangerous breathing trouble, also calls for immediate local medical contact; do not assume either is a necessary part of an “experience” or wait for it to end. The [NHS explains the urgency of suspected poisoning](https://www.nhs.uk/conditions/poisoning/) and [sudden confusion](https://www.nhs.uk/symptoms/confusion/), but UK telephone numbers do not apply everywhere. Threats, violence or confinement call for a separate safe route to local emergency protection. Questions about a study or retreat can wait until urgent needs are addressed.

## I. A powerful event and treatment are different claims

An intense encounter can matter deeply to someone. That does not establish that a substance, ceremony or retreat treats every participant’s substance use disorder. Psilocybin, ayahuasca and ibogaine differ in composition, research setting and risks. Alcohol findings cannot automatically be transferred to opioids, tobacco or cannabis; clinical-program findings cannot be transferred to a tourist retreat.

It helps to distinguish four claims: “I felt a change,” “a measured group outcome changed,” “a comparison supports attributing change to an intervention,” and “this particular service is available and safe for me.” The first three do not prove the fourth. A destination country, a claim of traditional origins or a facilitator’s story cannot replace medical assessment and checking actual conditions.

## II. What the psilocybin alcohol study showed

In a [US randomized study by Bogenschutz and colleagues](https://pubmed.ncbi.nlm.nih.gov/36001306/), 95 adults with alcohol dependence were assigned to psilocybin or an active comparator; both groups received structured psychotherapy. The primary analysis included 93 people who received study medication. Across 32 weeks after the first session, the proportion of heavy-drinking days was lower in the psilocybin group. This is a specific result among selected adults at two academic centers, not a “permanent cure” percentage.

People with certain major co-occurring conditions, medical contraindications or specified medications were excluded. No serious adverse events were recorded among psilocybin recipients in this small selected trial, but that does not guarantee safety for someone else. An advertising summary cannot separate every contribution of the drug, psychotherapy and expectations. [The FDA’s final July 2026 guidance for clinical investigations](https://www.fda.gov/media/169694/download) addresses difficulties with blinding, the need to assess lasting effects and the role of psychological support. It is US research guidance, not permission for or approval of retreats.

## III. Ayahuasca: observing a whole program does not isolate a ritual

An [evaluation of one Peruvian therapeutic community](https://pubmed.ncbi.nlm.nih.gov/37615330/) included 52 participants in an integrated program involving ayahuasca and other support. At a one-year follow-up, substance-use severity and some other measures had moved in a favorable direction, with substantial variation between people. There was no randomized comparison group. The design cannot establish how much of the change came from the brew, other parts of the program, selection of motivated participants or time.

That work did not test every retreat, a short trip or a “weekend ceremony.” A participant’s positive account deserves respect as their experience, but it is not a forecast for someone else. Ritual or cultural significance may matter voluntarily; belief in it is not a condition for ordinary care.

## IV. Ibogaine: a cardiac risk does not disappear behind “screening”

A [small Dutch observational study of ibogaine safety](https://pmc.ncbi.nlm.nih.gov/articles/PMC9292417/) involved 14 carefully selected people with opioid use disorder receiving maintenance treatment. They were observed in a university medical center, and people with certain important cardiac and other risks were excluded. Even there, researchers observed clinically important changes in the heart’s electrical activity and temporary severe problems with coordination. Not seeing one type of dangerous arrhythmia in 14 people does not rule it out elsewhere.

In [October 2026 the FDA requested information to design early ibogaine studies](https://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-support-ibogaine-research) and explicitly identified serious safety concerns. A request for evidence, permission to research, or a retreat intake form does not establish proven effectiveness or show that a particular center can prevent complications. A published research monitoring procedure is no guide for self-administration.

## V. Trial selection does not transfer to a retreat

Clinical studies specify who can enter, who assesses health, which events are tracked and who responds to complications. Even careful selection cannot guarantee an individual result. Outside a study, substance composition, staff preparation, access to medical care, consent to touch, length of observation and links to continuing treatment may differ. A “medical screening passed” badge does not explain those differences.

Useful questions are who will independently assess health and current medication, who responds to medical deterioration, what happens if someone refuses or wants to leave, how a boundary violation is handled, and what follow-up contact exists. Check answers against a real local service, price, language, waiting time, local rules and the ability to reach a qualified clinician. This article verifies no retreat’s access, legality, confidentiality or quality.

## VI. Entry requirements are no reason to interrupt prescribed care

If an organizer requires stopping a prescribed medicine, changing how it is taken, or undergoing a “cleanse” before arrival, discuss the risks first with the prescriber or another qualified local clinician. Do not devise a home withdrawal plan or test substance combinations on yourself. [For benzodiazepines, the FDA](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class) distinguishes potential medical benefit, physical adaptation and risks; abrupt self-discontinuation can be dangerous. Physical adaptation to a prescription is not automatically a substance use disorder.

With opioid use disorder, a promise of “one session” is a particularly poor reason to displace continuing care. [The CDC’s US clinical page](https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html) associates medication treatment with lower overdose and mortality risk and does not recommend detoxification alone without that treatment. A qualified professional and the person develop the individual plan; the CDC page does not establish equal availability of services or medicines in every country.

## VII. Consent, boundaries and other people’s safety

A person needs understandable information about proposed actions, risks, refusal and who will be present when judgment may change. An intense experience does not remove boundaries around touch or the option to seek separate safe protection from coercion or violence. If a helper or relative is threatened, their safety also deserves a separate local protection route; a joint conversation with the threatening person is not a mandatory first step.

Children should not monitor substance use, interpret negotiations, hold medicines or care for an adult after an intervention. If a parent is away or temporarily unable to care for a child, a particular capable adult must actually take over care. An organizer answering the phone, a future appointment or a promise to “be back tonight” is not that care. Local consent, reporting and confidentiality rules differ; this article makes no universal guarantee.

## VIII. Help is possible without an intense experience

Someone can approach an operating local medical or psychological service with a simple request: “I need an assessment of my substance-use difficulties and current medicines. Which options are actually available, what do they cost, what language is offered, how long is the wait, and who can I contact next?” Belief in a ritual, perfect abstinence or a promise to change one’s whole life in one trip is not required to ask for help. If one service is unsuitable, it is reasonable to ask about another real entry point, while recognizing that no immediate opening is guaranteed.

Do not automatically call new symptoms after an intense intervention “integration.” For new sudden confusion by itself, dangerous breathing trouble, or suspected poisoning even before symptoms, contact a local emergency medical service immediately. Seek separate safe protection for threats, confinement or violated boundaries. Support afterward may be needed, but it cannot replace emergency assessment.

## Sources and limits

- [FDA, Psychedelic Drugs: Considerations for Clinical Investigations](https://www.fda.gov/media/169694/download): final nonbinding US research guidance, July 2026; selected PDF sections read, not evidence that a retreat is safe.
- [FDA, public input to support ibogaine research](https://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-support-ibogaine-research): US news release of 5 October 2026 requesting input for early research, not a treatment approval.
- [Bogenschutz et al., psilocybin-assisted psychotherapy for AUD](https://pubmed.ncbi.nlm.nih.gov/36001306/): indexed original trial metadata and abstract, US, 2022; full article could not be read, and the conclusion is limited to selected participants and accompanying psychotherapy.
- [Knuijver et al., ibogaine cardiac safety](https://pmc.ncbi.nlm.nih.gov/articles/PMC9292417/): original Dutch open-label observation, online 2021/issue 2022, 14 selected patients; not an effectiveness trial. Its CC BY-NC license does not authorize commercial translation here.
- [Rush et al., ATOP one-year outcomes](https://pubmed.ncbi.nlm.nih.gov/37615330/): indexed original observational-study metadata and abstract from one integrated center in Peru, 2024; full article was unavailable during reading and there was no randomized comparator.
- [CDC, Opioid Use Disorder: Treating](https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html): US clinician page, 9 April 2024, on medication treatment; local access unverified.
- [FDA, benzodiazepine drug safety communication](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class): US regulatory communication of 23 September 2020 about one medicine class, not a personal withdrawal plan or interaction list.
- [NHS, Sudden confusion](https://www.nhs.uk/symptoms/confusion/): UK patient page reviewed 28 May 2024; new sudden confusion alone requires urgent help.
- [NHS, Poisoning](https://www.nhs.uk/conditions/poisoning/): UK patient page reviewed 12 June 2025; suspected poisoning needs immediate help before symptoms.

## Tags

psychedelic retreats, treatment research, psilocybin, ayahuasca, ibogaine, cardiac risks, consent, medical assessment, prescribed medicines, opioid use disorder, emergency care, child safety

## About the authors

Andrey Zarinsh is the author and founder of United Wisdom. He studies inner transformation, the unity of traditions, cross-cultural dialogue, and contemporary spiritual discipline. Instagram: @andrey.zarinsh.

Maria Evilkut is a co-author of United Wisdom. Alongside her research, she seeks to test these ideas in practice and observe how the principles of unity and mutual understanding work in real life between people and cultures. Instagram: @ilkutki.

## Content date

15 October 2026. English version.